BCL2 and osteosarcoma: Several studies on human cancer cells and mouse models have highlighted the effectiveness of co-targeting anti-apoptotic Bcl-2 proteins, as in osteosarcoma, neuroblastoma, and lung and colorectal carcinomas [67,68,69].